Belantamab Mafodotin
Belantamab Mafodotin Uses, Dosage, Side Effects, Food Interaction and all others data.
Belantamab Mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF).
Belantamab Mafodotin was granted FDA approval on 5 August 2020.
Belantamab Mafodotin treats multiple myeloma through antibody dependant cell mediated cytotoxicity as well as G2/M cell cycle arrest. It has a narrow therapeutic index due to the incidence of adverse effects, and a long duration of action as it is given every 3 weeks. Patients should be counselled regarding the risk of keratopathy.
| Trade Name | Belantamab Mafodotin |
| Generic | Belantamab mafodotin |
| Belantamab mafodotin Other Names | Belantamab mafodotin, Belantamab Mafodotin-blmf |
| Weight | 100mg |
| Type | Intravenous powder for injection |
| Protein binding | Monoclonal antibodies are generally not protein bound. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Belantamab Mafodotin is an anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
Belantamab Mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Belantamab Mafodotin is also used to associated treatment for these conditions: Relapsed Or Refractory Multiple Myeloma
How Belantamab Mafodotin works
Belantamab Mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF). Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody dependant cell mediated cytoxicity.
BCMA is uniquely expressed on CD138-positive myeloma cells. Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells. Belantamab Mafodotin binds to BCMA, is internalised into cells, and releases MMAF.
The MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis.
Toxicity
Data regarding overdose is not readily available. However, keratopathy was seen in 71% of patients.
Food Interaction
No interactions found.Volume of Distribution
The mean steady state volume of distribution of belantamab mafodotin was 11 L.
Elimination Route
Belantamab Mafodotin at a dose of 2.5mg/kg reaches a Cmax of 42 µg/mL, with a Tmax of 0.78 hours, and an AUC of 4666 µg*h/mL.
Half Life
The terminal half life of belantamab mafodotin was 12 days after the first dose and 14 days at steady state.
Clearance
The clearance of belantamab mafodotin was 0.9 L/day after the first dose and 0.7 L/day at steady state.
Elimination Route
Monoclonal antibodies are eventually phagocytosed and broken down to smaller peptides and amino acids which are eliminated in a similar fashion to other proteins. Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.
Innovators Monograph
You find simplified version here Belantamab Mafodotin
